Camptothecin in sterically stabilized phospholipid micelles: A novel nanomedicine

被引:83
作者
Koo, Otilia M. [1 ]
Rubinstein, Israel [1 ,2 ,4 ]
Onyuksel, Hayat [1 ,3 ]
机构
[1] Univ Illinois, Dept Biopharmaceut Sci, Chicago, IL USA
[2] Univ Illinois, Dept Med, Chicago, IL USA
[3] Univ Illinois, Dept Bioengn, Chicago, IL USA
[4] Jesse Brown Vet Affairs Med Ctr, Chicago, IL USA
基金
美国国家卫生研究院;
关键词
Camptothecin; Phospholipid; Micelles; Formulation; Lyophilization;
D O I
10.1016/j.nano.2004.11.002
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Background: Camptothecin (CPT) is a well-established topoisomerase I inhibitor against a broad spectrum of cancers. However, poor aqueous solubility, instability, and toxic effects to normal tissues have limited CPT clinical development. Recently, sterically stabilized micelles (SSM) composed of polyethylene glycol (PEGylated) phospholipids have been introduced as safe, biocompatible nanocarriers for the delivery of poorly water-soluble drugs. It was the aim of this study to develop and evaluate in vitro camptothecin-containing SSM (CPT-SSM) as a novel nanomedicine for parenteral administration. Methods: The solubilization potential, stability, and in vitro cytotoxicity of CPT in SSM were studied. Lyophilization of CPT-SSM under controlled conditions was also studied. Results: The mean size of CPT-SSM was found to be similar to 14 nm with a narrow size distribution. CPT-SSM were prepared by coprecipitation reconstitution. At a concentration of 15 mmol/L of PEGylated phospholipids where no micelle-micelle interaction was observed, CPT solubilization in SSM was 25-fold higher than CPT in buffer. We determined that CPT can be solubilized in SSM up to molar ratios of CPT/lipid = 0.0063:1. Above this critical molar ratio, heterogeneous systems of CPT-SSM and CPT self-aggregated particles were formed. CPT in SSM was at least 3 times more stable and 3-fold more cytotoxic to MCF-7 cells than CPT alone. Furthermore, CPT-SSM alone was lyophilized without additional lyoprotectants and cryoprotectants and reconstituted without any significant change in properties. Conclusion: We have shown that CPT in SSM is a promising nanomedicine with improved drug solubility, stability, freeze-drying properties, and anticancer activity. It is anticipated that, because of the nanosize and steric stability of the micelles, CPT-SSM will be passively targeted to solid cancers in vivo, resulting in high drug concentration in tumors and reduced drug toxicity to the normal tissues. (C) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:77 / 84
页数:8
相关论文
共 37 条
  • [21] Mukerjee P., 1971, Critical Micelle Concentrations of Aqueous Surfactant Systems, V36
  • [22] Spectroscopic and biochemical characterisation of self-aggregates formed by antitumor drugs of the camptothecin family - Their possible role in the unique mode of drug action
    Nabiev, I
    Fleury, F
    Kudelina, I
    Pommier, Y
    Charton, F
    Riou, JF
    Alix, AJP
    Manfait, M
    [J]. BIOCHEMICAL PHARMACOLOGY, 1998, 55 (08) : 1163 - 1174
  • [23] Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents
    Natelson, EA
    Giovanella, BC
    Verschraegen, CF
    Fehir, KM
    DeIpolyi, PD
    Harris, N
    Stehlin, JS
    [J]. CAMPTOTHECINS: FROM DISCOVERY TO THE PATIENT, 1996, 803 : 224 - 230
  • [24] Camptothecin and taxol: Historic achievements in natural products research
    Oberlies, NH
    Kroll, DJ
    [J]. JOURNAL OF NATURAL PRODUCTS, 2004, 67 (02): : 129 - 135
  • [25] Interactions of VIP with rigid phospholipid bilayers:: implications for vasoreactivity
    Önyüksel, H
    Ashok, B
    Dagar, S
    Sethi, V
    Rubinstein, I
    [J]. PEPTIDES, 2003, 24 (02) : 281 - 286
  • [26] A novel formulation of VIP in sterically stabilized micelles amplifies vasodilation in vivo
    Önyüksel, H
    Ikezaki, H
    Patel, M
    Gao, X
    Rubinstein, I
    [J]. PHARMACEUTICAL RESEARCH, 1999, 16 (01) : 155 - 160
  • [27] Optimization of the sulforhodamine B colorimetric assay
    Papazisis, KT
    Geromichalos, GD
    Dimitriadis, KA
    Kortsaris, AH
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 1997, 208 (02) : 151 - 158
  • [28] Nanosuspensions in drug delivery
    Rabinow, BE
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (09) : 785 - 796
  • [29] Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA
    Redinbo, MR
    Stewart, L
    Kuhn, P
    Champoux, JJ
    Hol, WGJ
    [J]. SCIENCE, 1998, 279 (5356) : 1504 - 1513
  • [30] SCHAEPPI U, 1974, CANCER CHEMOTH REP 3, V5, P25